前列腺特異性抗原 (PSA) 檢測市場規模、佔有率和成長分析：按檢測類型、技術、應用、最終用戶、檢體類型、產品類型和地區分類－2026-2033 年產業預測

2024 年全球前列腺特異性抗原 (PSA) 檢測市值為 51 億美元，預計到 2025 年將成長至 54.6 億美元，到 2033 年將成長至 94.6 億美元，預測期（2026-2033 年）複合年成長率為 7.1%。

全球前列腺特異性抗原 (PSA) 檢測市場涵蓋診斷試劑盒、自動化分析儀以及用於前列腺癌篩檢和後續觀察的相關服務。鑑於攝護腺癌是男性第二常見癌症，早期檢測的需求日益成長，凸顯了這些檢測的重要性。近年來，技術進步推動了高靈敏度免疫檢測和即時檢測 (PoC) 設備的研發，提高了檢測的可及性並縮短了檢測結果的獲取時間，尤其是在印度、巴西和中國等新興市場。此外，精準醫療的興起也增加了對高通量檢測的需求，並推動了檢查室自動化領域的投資。這些進步，加上保險報銷體系改革強調早期檢測，使得企業能夠利用 PSA 檢測中展現出的臨床價值和成本效益，將其轉化為商機。

全球前列腺特異性抗原 (PSA) 檢測市場的成長要素

隨著大眾和醫療專業人員對前列腺癌早期檢測益處的認知不斷提高，越來越多的男性開始定期接受PSA檢測。這一趨勢也帶動了對診斷試劑盒及相關服務的需求。醫療機構正將PSA篩檢納入常規預防保健流程，這不僅提高了患者的參與度，也促進了市場的穩定成長。此外，公眾意識的提升也推動了針對不同人群的檢測宣傳活動，從而進一步推動了全球前列腺特異性抗原檢測市場的持續擴張。

全球前列腺特異性抗原 (PSA) 檢測市場的限制因素

全球前列腺特異性抗原 (PSA) 檢測市場面臨嚴峻挑戰，因為 PSA 檢測容易出現偽陽性結果。這個問題導致患者和醫療服務提供者產生不確定性，常常造成不必要的侵入性檢查，並加劇焦慮。此類假陽性結果會削弱人們對篩檢過程的信心，使一些臨床醫生傾向於採取更保守的檢測方法。這種謹慎的態度可能會阻礙常規檢測的推廣，尤其是在低風險族群中，最終阻礙市場成長。此外，對過度診斷的擔憂可能會引發公眾討論並影響政策決策，從而限制 PSA 檢測在國家篩檢計畫中的廣泛應用。

全球前列腺特異性抗原 (PSA) 檢測市場趨勢

在全球前列腺特異性抗原 (PSA) 檢測市場中，個人化篩檢方案正呈現出顯著趨勢，這主要得益於基因組學的進步和風險分層技術的改進。醫療專業人員正日益重視制定個人化篩檢方案，將 PSA 檢測結果與遺傳標記、家族病史和生活方式因素相結合，以最佳化檢測準確性。這種個人化方法不僅旨在提高攝護腺疾病的早期診斷率，還能最大限度地減少侵入性切片檢查的需求，進而提升病患的安全性和舒適度。此外，整合多種資料點的決策支援工具的應用，也促進了以患者為中心的醫療服務，使臨床醫生能夠根據不同的風險狀況和長期管理策略做出更明智的決策。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 疾病流行病學

全球前列腺特異性抗原 (PSA) 檢測市場規模：按檢測類型分類

• 總PSA檢測
• 免費PSA檢測
• 聯合PSA檢測
• PSA速度測試和PSA密度測試

全球前列腺特異性抗原 (PSA) 檢測市場規模：依技術分類

• 免疫測量
• 化學冷光免疫檢測（CLIA）
• 酵素免疫分析法（ELISA）
• 即時檢測

全球前列腺特異性抗原 (PSA) 檢測市場規模：按應用分類

• 攝護腺癌篩檢
• 前列腺癌的後續觀察
• 良性攝護腺增生（BPH）的評估
• 治療後後續觀察

全球前列腺特異性抗原 (PSA) 檢測市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 泌尿系統診所
• 門診部

全球前列腺特異性抗原 (PSA) 檢測市場規模：按檢體類型分類

• 血清
• 電漿

全球前列腺特異性抗原 (PSA) 檢測市場規模：按產品類型分類

• 檢測套組和試劑
• 儀器/分析儀
• 耗材和配件

全球前列腺特異性抗原 (PSA) 檢測市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Laboratories
• Siemens Healthineers AG
• Sysmex Corporation
• bioMerieux SA
• DiaSorin SpA
• QuidelOrtho Corporation
• Becton, Dickinson and Company
• Tosoh Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• SD Biosensor, Inc.
• Wondfo Biotech Co., Ltd.
• Danaher Corporation
• Trivitron Healthcare Pvt. Ltd.
• F. Hoffmann-La Roche Ltd.
• Fujirebio Holdings, Inc.
• Snibe Diagnostic Co., Ltd.
• Getein Biotech, Inc.
• Autobio Diagnostics Co., Ltd.
• BioVendor Group
• Meril Life Sciences Pvt. Ltd.

結論與建議

Global Prostate Specific Antigen Test Market size was valued at USD 5.1 Billion in 2024 and is poised to grow from USD 5.46 Billion in 2025 to USD 9.46 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The global market for prostate specific antigen (PSA) testing encompasses diagnostic kits, automated analyzers, and ancillary services aimed at prostate cancer screening and monitoring. The rising need for early detection, fueled by prostate cancer being the second most prevalent cancer in men, emphasizes the critical nature of these tests. Recent advancements have led to high sensitivity immunoassays and point-of-care devices, enhancing access and reducing turnaround times, particularly in emerging markets like India, Brazil, and China. Additionally, the integration of precision medicine has prompted a demand for high throughput assays, driving laboratory automation investments. This evolution, alongside reimbursement reforms favoring early detection, enables firms to capitalize on advancements demonstrating clinical value and cost-effectiveness in PSA testing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prostate Specific Antigen Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Prostate Specific Antigen Test Market Segments Analysis

Global prostate specific antigen test market is segmented by test type, technology, application, end user, sample type, product type and region. Based on test type, the market is segmented into Total PSA Test, Free PSA Test, Complexed PSA Test and PSA Velocity & PSA Density Tests. Based on technology, the market is segmented into Immunoassays, Chemiluminescence Immunoassays (CLIA), Enzyme-Linked Immunosorbent Assays (ELISA) and Point-of-Care Testing. Based on application, the market is segmented into Prostate Cancer Screening, Prostate Cancer Monitoring, Benign Prostatic Hyperplasia (BPH) Assessment and Post-Treatment Surveillance. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Specialty Urology Clinics and Ambulatory Care Centers. Based on sample type, the market is segmented into Blood Serum and Plasma. Based on product type, the market is segmented into Test Kits & Reagents, Instruments & Analyzers and Consumables & Accessories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Prostate Specific Antigen Test Market

The increasing awareness among the public and healthcare professionals about the advantages of early detection of prostate cancer is leading to a rise in the number of men opting for regular PSA testing. This trend is consequently boosting the demand for diagnostic kits and associated services. Healthcare providers are incorporating PSA screening into routine preventive health measures, which enhances patient engagement and contributes to consistent market growth. Additionally, this growing awareness fuels educational efforts that encourage the widespread adoption of testing among various demographics, thereby supporting the ongoing expansion of the global prostate-specific antigen test market.

Restraints in the Global Prostate Specific Antigen Test Market

The Global Prostate Specific Antigen (PSA) Test market faces significant challenges due to the tendency of PSA testing to yield false positive results. This issue generates uncertainty among patients and healthcare providers, often resulting in unnecessary invasive procedures and increased anxiety levels. Such outcomes can undermine confidence in the screening process, leading some clinicians to favor more conservative testing approaches. This caution can deter the routine ordering of tests, particularly among low-risk populations, ultimately hindering market growth. Moreover, concerns regarding overdiagnosis contribute to public discussions that may affect policy decisions, potentially limiting the wider use of PSA assays in national screening initiatives.

Market Trends of the Global Prostate Specific Antigen Test Market

The Global Prostate Specific Antigen (PSA) Test market is witnessing a significant trend towards personalized screening protocols, fueled by advancements in genomics and enhanced risk stratification techniques. Healthcare providers are increasingly combining PSA test outcomes with genetic markers, family histories, and lifestyle factors to create individualized screening plans that optimize detection accuracy. This tailored approach not only aims to improve early diagnosis of prostate conditions but also minimizes the necessity for invasive biopsies, thereby enhancing patient safety and comfort. Additionally, the use of decision-support tools that integrate diverse data points is facilitating more patient-centered care, allowing clinicians to confidently navigate varying risk profiles and long-term management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Prostate Specific Antigen Test Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Total PSA Test
• Free PSA Test
• Complexed PSA Test
• PSA Velocity & PSA Density Tests

Global Prostate Specific Antigen Test Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunoassays
• Chemiluminescence Immunoassays (CLIA)
• Enzyme-Linked Immunosorbent Assays (ELISA)
• Point-of-Care Testing

Global Prostate Specific Antigen Test Market Size by Application & CAGR (2026-2033)

• Market Overview
• Prostate Cancer Screening
• Prostate Cancer Monitoring
• Benign Prostatic Hyperplasia (BPH) Assessment
• Post-Treatment Surveillance

Global Prostate Specific Antigen Test Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Specialty Urology Clinics
• Ambulatory Care Centers

Global Prostate Specific Antigen Test Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood Serum
• Plasma

Global Prostate Specific Antigen Test Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Test Kits & Reagents
• Instruments & Analyzers
• Consumables & Accessories

Global Prostate Specific Antigen Test Market Size & CAGR (2026-2033)

• North America (Test Type, Technology, Application, End User, Sample Type, Product Type)
  • US
  • Canada
• Europe (Test Type, Technology, Application, End User, Sample Type, Product Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Application, End User, Sample Type, Product Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Application, End User, Sample Type, Product Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Application, End User, Sample Type, Product Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tosoh Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SD Biosensor, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wondfo Biotech Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trivitron Healthcare Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Snibe Diagnostic Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getein Biotech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autobio Diagnostics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVendor Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meril Life Sciences Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations